Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

Business Wire August 18, 2021

The Law Offices of Frank R. Cruz Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

Business Wire August 18, 2021

SHAREHOLDER ALERT: Investigation of Sesen Bio, Inc. Announced by Holzer & Holzer, LLC

Newsfile August 18, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sesen Bio, Inc. - SESN

Newsfile August 17, 2021

Federman & Sherwood Announces an Investigation into Sesen Bio

Business Wire August 17, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sesen Bio, Inc. - SESN

PR Newswire August 16, 2021

SESEN BIO INVESTIGATION: Block & Leviton Investigates Sesen Bio For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile August 16, 2021

SESEN BIO INVESTIGATION: Block & Leviton Investigates Sesen Bio For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile August 13, 2021

Sesen Bio Receives Complete Response Letter from FDA for Vicineum(TM) (oportuzumab monatox-qqrs)

Business Wire August 13, 2021

Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum(TM)

Business Wire August 11, 2021

Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum(TM)

Business Wire August 9, 2021

Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum(TM) in Turkey

Business Wire August 5, 2021

Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum(TM)

Business Wire August 2, 2021

Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum(TM) in the US

Business Wire July 26, 2021

Sesen Bio Announces New Appointments to its Board of Directors

Business Wire July 21, 2021

Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum(TM) in China

Business Wire July 20, 2021

Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum(TM)

Business Wire July 14, 2021

Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 2, 2021

Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 18, 2021

Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical

Business Wire June 2, 2021